Vestal Point Capital, LP Immatics N.V. Transaction History
Vestal Point Capital, LP
- $1.4 Trillion
- Q1 2025
A detailed history of Vestal Point Capital, LP transactions in Immatics N.V. stock. As of the latest transaction made, Vestal Point Capital, LP holds 7,192,700 shares of IMTX stock, worth $39.8 Million. This represents 2.32% of its overall portfolio holdings.
Number of Shares
7,192,700
Previous 6,275,000
14.62%
Holding current value
$39.8 Million
Previous $44.6 Billion
27.29%
% of portfolio
2.32%
Previous 2.65%
Shares
6 transactions
Others Institutions Holding IMTX
# of Institutions
82Shares Held
91.4MCall Options Held
201KPut Options Held
109K-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.7MShares$81.3 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$52 Million1.77% of portfolio
-
Suvretta Capital Management, LLC New York, NY9.14MShares$50.6 Million1.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.58MShares$47.6 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$40.3 Million0.39% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $422M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...